{"question": "为建立体外诊断试剂的临床性能，中美法规均提出了具体要求。请选择同时符合两国法规核心要求的选项组合：\n① 使用来自目标适应症人群的、覆盖设备测量范围的、特征明确的患者样本。\n② 必须与已合法上市的、具有相似适应症的对照设备进行方法学比较。\n③ 临床验证结果必须能证明基于疾病存在与否的临床敏感性和临床特异性。\n④ 必须提供由测试足够数量表观健康个体样本生成的预期/参考值。", "choices": ["A. ①②③", "B. ①③④", "C. ②③④", "D. ①②③④"], "answer": "B", "type": "Comparative", "explanation": "组合①③④正确。①和③是美国FDA法规（K）项下的明确要求。④是美国FDA法规（L）项下的要求。中国NMPA法规在提供的文本中未详细展开临床性能建立的具体数据要求，但其通用原则要求证明产品的安全有效性，与①③④所体现的严谨科学验证逻辑在监管精神上一致。②“必须与已合法上市的对照设备进行比较”是美国FDA法规（I）项的明确要求，但中国NMPA法规在提供的文本中未将此列为强制性通用要求，可能根据产品类别有所不同，因此不属于“同时符合两国法规核心要求”的必然项。", "category": "Medical_Devices", "related_concept": "clinical performance establishment", "id": "CO_P_00574_009", "match_type": "strong", "match_score": 0.8451760143931965, "lang": "CN", "source_cn": "定制式医疗器械监督管理规定（试行）.txt", "source_us": "PART_866IMMUNOLOGY_AND_MICROBIOLOGY_DEVICES.txt", "old_id": "comp_0014_0024_3"}
{"question": "Regarding hearing denial and subsequent judicial review rights, which statement is correct?", "choices": ["A. Both systems allow judicial review after hearing denial, but only the US system has explicit time limits for filing such review.", "B. Both systems allow judicial review after hearing denial, but only the Chinese system has explicit time limits for filing such review.", "C. Only the US system explicitly addresses judicial review following hearing denial on specific issues.", "D. Both systems explicitly address judicial review following hearing denial with similar time limit provisions."], "answer": "C", "type": "Comparative", "explanation": "US FDA regulations explicitly address judicial review following hearing denial, specifying that failure to file within statutory periods constitutes waiver of judicial review rights. Chinese NMPA regulations mention judicial review generally but do not specifically address the scenario of hearing denial followed by judicial review with the same level of procedural detail.", "category": "General_FDA", "related_concept": "hearing denial", "id": "CO_P_00791_006", "match_type": "strong", "match_score": 0.8091307545501216, "lang": "EN", "source_cn": "中华人民共和国行政复议法（已修改）.txt", "source_us": "PART_12FORMAL_EVIDENTIARY_PUBLIC_HEARING.txt", "old_id": "comp_0007_0003_3"}
{"question": "关于标准操作规程的审查与批准，中美法规的共同核心要求是什么？", "choices": ["A. 必须由质量保证人员审查", "B. 必须由机构负责人批准", "C. 必须由指定负责人审查批准后方可生效", "D. 必须经过外部专家评审"], "answer": "C", "type": "Comparative", "explanation": "中国法规要求标准操作规程需经质量保证人员审查、机构负责人批准后方可生效；美国法规要求实施前必须由负责人审查批准。两者都强调指定负责人的审查批准是生效前提，这是确保规程合规有效的关键控制点。", "category": "Drugs", "related_concept": "procedure review and approval", "id": "CO_P_00346_001", "match_type": "strong", "match_score": 0.7990889007698694, "lang": "CN", "source_cn": "药物非临床研究质量管理规范（2017年第34号）.txt", "source_us": "PART_1271HUMAN_CELLS_TISSUES_AND_CELLULAR_AND_TISS.txt", "old_id": "comp_0010_0013_1"}
{"question": "请判断以下两个陈述：\n陈述1：中美法规均要求对生产和检验过程中的温度进行严格控制，并记录具体控制范围。\n陈述2：中美法规均强调校准记录必须具备可追溯性，需包含所用计量标准器具的关键信息。", "choices": ["A. 两个陈述都正确", "B. 陈述1正确，陈述2错误", "C. 陈述1错误，陈述2正确", "D. 两个陈述都错误"], "answer": "C", "type": "Comparative", "explanation": "陈述1错误。美国法规在提供的工艺描述中确实明确了多个精确的温度控制点（如77-82°C，49-54°C等），体现了对关键工艺参数（温度）的严格控制。但中国提供的法规文本主要围绕设备校准和水系统，未具体涉及生产工艺的温度控制要求，因此不能得出“均要求”的结论。陈述2正确。中国法规明确要求校准记录应标明计量标准器具的名称、编号、校准有效期等以确保可追溯性。美国法规在系统适用性测试部分，通过对参考标准品制备、色谱条件、计算公式的详细规定，同样隐含了确保整个分析过程（包括仪器、试剂、方法）可追溯、可复现的逻辑，这是数据可靠性的基础。两者在确保关键过程记录可追溯的原则上是一致的。", "category": "Drugs", "related_concept": "temperature control, calibration records and traceability", "id": "CO_P_00260_006", "match_type": "strong", "match_score": 0.7728503141733116, "lang": "CN", "source_cn": "药品生产质量管理规范（2010年修订）（卫生部令第79号）.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0016_0079_3"}
{"question": "关于药品标签中放射性产品特性的描述要求，中美药监法规的主要差异是什么？", "choices": ["A. 中国法规要求详细说明物理衰变特性，美国法规则无此要求", "B. 美国法规明确要求声明重要核物理特性，中国法规未在通用标签修订条款中专门提及", "C. 两国法规均要求在产品为放射性时声明其物理特性，但具体项目完全一致", "D. 中国法规对放射性产品的标签要求比美国法规更为详细和严格"], "answer": "B", "type": "Comparative", "explanation": "美国法规（如21 CFR 201.57）明确规定，若产品具有放射性，其标签必须包含重要核物理特性的声明，例如主要辐射发射数据、外部辐射及物理衰变特性。中国提供的法规文本主要聚焦于药品说明书安全性内容（如不良反应、禁忌等）的变更流程，并未在通用标签修订条款中专门、明确地列举放射性产品特性的描述要求。因此，美国法规在此方面有更直接和具体的规定。选项A错误，因为美国法规有此要求；选项C错误，因为中国文本未展示对应具体要求；选项D错误，基于给定文本无法得出中国要求更严格的结论。", "category": "Drugs", "related_concept": "radioactive product characteristics", "id": "CO_P_00150_007", "match_type": "strong", "match_score": 0.8419834157255961, "lang": "CN", "source_cn": "已上市中药变更事项及申报资料要求.txt", "source_us": "PART_201LABELING.txt", "old_id": "comp_0007_0016_1"}
